Top Markets
Coin of the day
Altamira Therapeutics Ltd. Altamira Therapeutics Ltd.

Altamira Therapeutics Ltd.

CYTO
株式のランク #38206
Altamira Therapeutics Ltd. is a biotechnology firm dedicated to pioneering new... Altamira Therapeutics Ltd. is a biotechnology firm dedicated to pioneering new treatments for critical medical needs that are currently underserved. Its marketed offerings include Bentrio, a non-pharmaceutical nasal spray designed for individual protection against prevalent airborne viruses and allergens. The company is also heavily invested in developing RNA therapeutics specifically for extrahepatic targets. This includes their preclinical OligoPhore and SemaPhore platforms, engineered for the effective delivery of oligonucleotides and mRNA. In its clinical-stage portfolio, AM-125 is undergoing Phase II trials for the intranasal treatment of vertigo. Additionally, Keyzilen and Sonsuvi are both in Phase III clinical development; Keyzilen is focused on acute inner ear tinnitus, and Sonsuvi addresses acute inner ear hearing loss. Established in 2003 and headquartered in Hamilton, Bermuda, Altamira Therapeutics conducts operations across Switzerland, the United States, Europe, and Australia. The company officially adopted the name Altamira Therapeutics Ltd. in July 2021, prior to which it was known as Auris Medical Holding Ltd.
株価
$0.3
最終同期: 2026-02-10
時価総額
$1.13M
変化(1日)
0.00%
変化(1年)
328.57%
BM
取引 Altamira Therapeutics Ltd. (CYTO)

カテゴリー

Altamira Therapeutics Ltd.(CYTO)の配当利回りの履歴
Altamira Therapeutics Ltd.(銘柄コード: CYTO)の配当利回り(TTM)は2026時点で0です。
過去5年間の平均配当利回り: 0.00%
Altamira Therapeutics Ltd.(CYTO)の2026から2026までの配当利回りの履歴
各年末時点の配当利回り(TTM)
配当利回り 変化
提供された日付のデータは十分ではありません。
類似企業または競合他社の配当利回り(TTM)